Aquestive Therapeutics, Inc. AQST R2KR3KPHARMA
Company Overview
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Recent Developments
- Dec 2025 Revenue of $44.55M (-22.6% YoY); net profit $-83.78M.
- Trailing 12 Months Year-on-year growth — revenue +38.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.65% |
| 1 Year: | 38.10% |
Stock Price Performance
| 1 Year: | -0.25% |
| 6 Months: | -1.96% |
| 3 Months: | +7.24% |
| 1 Month: | -17.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.04 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -5.7% CAGR over 5 years.
- Trading 46.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AQST Aquestive Therapeutics, Inc. R2KR3KPHARMA | 4.00 | -6.06 | $502.05M | 0.00% | -62.98% | - | -5.65% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 23.41M | 13.93M | 13.27M | 16.82M | 12.64M | 11.13M | 12.42M | 16.42M | 8.77M | 21.68M | 8.26M | 7.15M | 11.12M | 15.35M | 13.29M | 12.27M | 13.27M | 11.46M | 11.13M | 13.24M | 13.00M | 12.05M | 20.10M | - | - | 8.72M | 10.00M | 12.81M | 13.02M | 14.45M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.65M | 4.56M | 4.51M | 5.84M | 3.47M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.07M | 5.44M | 8.30M | 7.18M | 10.98M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.43M | 16.81M | 19.78M | 36.02M | 15.18M |
| Operating Income | - | -4.06M | 10.42M | - | 5.30M | -32.71M | -9.21M | - | -13.07M | -18.69M | -11.00M | - | -13.86M | 395.00K | -13.78M | - | -8.53M | -6.52M | -7.97M | -9.74M | -12.76M | -8.85M | -4.61M | -4.21M | -2.38M | -8.96M | 55.00K | - | - | -19.36M | -11.37M | -11.48M | -28.84M | -4.20M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.51M | -9.13M | -11.03M | -27.46M | -4.01M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.28M | 4.28M | 4.27M | 4.27M | 3.94M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -14.00K | - | - | - | - | - |
| Net Income | -1.46M | -5.90M | 8.45M | -10.04M | 4.10M | -36.49M | -15.04M | -13.94M | -14.73M | -20.47M | -18.41M | -12.64M | -16.53M | -2.33M | -16.55M | -20.37M | -14.67M | -12.37M | -14.55M | -13.22M | -16.30M | -12.54M | 8.07M | -5.79M | -2.04M | -12.83M | -2.75M | - | - | -22.93M | -13.55M | -15.45M | -31.86M | -8.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.07 | -0.49 | - | -0.41 | -0.33 | -0.37 | -0.32 | -0.36 | -0.23 | 0.11 | -0.10 | -0.03 | -0.17 | -0.03 | - | - | -0.24 | -0.14 | -0.14 | -0.26 | -0.07 |
| R&D Expense | - | 4.84M | 5.68M | - | 4.90M | 7.99M | 4.53M | - | 4.30M | 8.15M | 5.06M | - | 4.35M | 3.85M | 7.26M | - | 3.66M | 4.26M | 4.73M | 4.77M | 5.20M | 3.23M | 3.55M | 3.47M | 3.20M | 5.93M | 4.16M | 5.27M | - | 5.36M | 4.11M | 4.53M | - | 4.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.92M | 67.43M | 52.61M | 45.85M | - | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | - | - | - | - | - | 19.39M | 20.83M | 17.87M | 18.55M |
| Gross Profit | - | - | - | - | - | 28.29M | 29.75M | 39.69M | 25.99M |
| Operating Expenses | - | - | - | - | - | 70.36M | 44.85M | 70.46M | 97.04M |
| Operating Income | -113.00K | -48.93M | -52.67M | -42.89M | - | -42.07M | -15.10M | -30.77M | -71.05M |
| EBITDA | - | - | - | - | - | -39.58M | 1.18M | -26.62M | -66.14M |
| Interest Expense | - | - | - | - | - | 12.44M | 7.46M | 16.82M | 17.10M |
| Pretax Income | - | - | - | - | - | -54.41M | -7.62M | -44.15M | -83.78M |
| Tax Provision | - | - | - | - | - | 0 | 245.00K | -14.00K | 0 |
| Net Income | -8.94M | -61.38M | -66.25M | -55.78M | - | -54.41M | -7.87M | -44.14M | -83.78M |
| Diluted EPS | - | - | - | -1.66 | - | -1.12 | -0.13 | -0.51 | -0.78 |
| R&D Expense | 22.13M | 23.11M | 20.57M | 19.89M | 17.05M | 17.48M | 13.10M | 20.28M | 17.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 43.12M | 86.85M | 78.48M | 62.88M | - | 57.07M | 57.42M | 101.42M | 160.43M |
| Current Assets | - | - | - | - | - | - | 39.89M | 40.97M | 88.22M | 149.27M |
| Cash & Equivalents | 9.21M | 17.38M | 60.60M | 49.33M | 31.81M | - | 27.27M | 23.87M | 71.55M | 121.17M |
| Inventory | - | - | - | - | - | - | 5.78M | 6.77M | 6.04M | 6.17M |
| Receivables | - | - | - | - | - | - | 3.27M | 5.57M | 4.92M | 8.01M |
| Total Liabilities | - | 69.61M | 76.77M | 84.60M | 111.38M | - | 175.62M | 163.91M | 161.58M | 194.09M |
| Current Liabilities | - | 15.35M | 32.95M | 18.55M | 21.10M | - | 39.53M | 18.31M | 18.86M | 47.61M |
| Long Term Debt | - | - | - | 70.00M | 51.50M | - | 33.45M | 27.51M | 32.50M | 27.52M |
| Total Debt | - | - | - | - | - | - | 57.49M | 33.32M | 38.00M | 42.48M |
| Total Equity | -57.20M | -26.50M | 10.08M | -6.12M | -48.50M | - | -118.55M | -106.49M | -60.16M | -33.66M |
| Shares Outstanding | - | - | - | - | - | - | 54.83M | 68.53M | 91.41M | 122.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 5.82M | -12.99M | -60.21M | -45.46M | - | -9.82M | -6.38M | -35.76M | -52.43M |
| Investing Cash Flow | -2.07M | -1.82M | -663.00K | -517.00K | - | -2.52M | -995.00K | -159.00K | -562.00K |
| Financing Cash Flow | 4.41M | 58.03M | 49.60M | 28.46M | - | 11.59M | 3.97M | 83.59M | 102.62M |
| Capital Expenditure | -2.07M | -1.82M | -663.00K | -517.00K | - | -2.52M | -995.00K | -159.00K | -562.00K |
| Free Cash Flow | 3.76M | -14.81M | -60.87M | -45.98M | - | -12.34M | -7.38M | -35.92M | -52.99M |
| Net Change in Cash | - | - | - | - | - | -751.00K | -3.40M | 47.67M | 49.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 59.3% | 58.8% | 69.0% | 58.3% |
| Operating Margin % | -0.2% | -72.6% | -100.1% | -93.6% | - | -88.2% | -29.9% | -53.5% | -159.5% |
| Net Margin % | -13.4% | -91.0% | -125.9% | -121.7% | - | -114.1% | -15.6% | -76.7% | -188.1% |
| ROE % | 33.8% | -608.9% | 1,082.1% | 115.0% | - | 45.9% | 7.4% | 73.4% | 248.9% |
| ROCE % | -0.4% | -90.8% | -87.9% | -102.7% | - | -239.8% | -38.6% | -37.3% | -63.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bratton Capital Management, LP | 7.82% | 9.81M | $46.90M |
| 2 | Blackrock Inc. | 6.43% | 8.07M | $38.57M |
| 3 | RTW Investments LP | 5.92% | 7.43M | $35.50M |
| 4 | Vanguard Capital Management LLC | 3.65% | 4.58M | $21.91M |
| 5 | Federated Hermes, Inc. | 2.48% | 3.11M | $14.88M |
| 6 | State Street Corporation | 2.33% | 2.93M | $14.00M |
| 7 | Geode Capital Management, LLC | 2.09% | 2.62M | $12.54M |
| 8 | Samsara BioCapital, LLC | 1.99% | 2.50M | $11.95M |
| 9 | Bank of America Corporation | 1.33% | 1.67M | $7.98M |
| 10 | Sio Capital Management, LLC | 1.18% | 1.49M | $7.10M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AQST
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOSklVNmZyaUFpN2VrbWtLdGdkbFptTmZINUpiTlZtNXh1dnJNM2JzMzFKS3pSeElGRnowRzlvNldnMkpxS1AxT0pXOVJ3Y2kzbzhqazIzMEkzVjNVVXVLZElsZU5RRDBCLW1CV01qNG9DZnZoLVgwQnRNVjNmbDFGSUNJYjFaMEZ2b2VXdn…
A 62,229-share transfer leaves Aquestive (AQST) director holding 161,715 shares directly. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNcFpGaHIybzhMdERaOHBoSFhxMmU0czlGV3owejNsYlVrdGQwZUFWRjhYbS0tODQwZlZtcVR5STFhQmFubWtwaXo0M1dKOThpQm5tNzI4YktJR2ZDckRFWGdyU3RidEVHcGdDUmdqbWgyeDd5Wkc4dE0wd19NUkVzVms1ZUlpbmt4UElCZV…
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFBEbzRPa0Jid0hzOTJtOER2cjhIVnpVdVNqU08wbnAyZVBwWHRSTjM5bDN0dmItV2dmNFpuQ3owZ2dBQTBqWnV3WEgxZndzUDhCQUNMMEt4Nm1USlE?oc=5" target="_blank">AQST News | AQUESTIVE THERAPEUTICS INC (NASD…
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPempaS09qa3FLcjBFbjl3S0w3WDlISzBaXzBiRW1uaFlJUmZ1QlBYc3EzUFhrWE1lVGtqa3pRYW9JOWFQTDRYak4xS0VoNDlWcXNsMGE5NzVzb2poU2V3QTdlS0JjNHg3VHhtcndMZHNwZ01SekpiR1ZGN2p2aDZncjFsNmtDOEJUTkpha3…
AQST Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9FT0ctNUhjUkVfeTk3VEI1cWZmb2U5V0dSVG5vSjlkblBZSkZoSXhUMzYxVk9xMVpyejQ0UU9ZbFA0MG5HemMtODNZZUQtTHdiMTFURVpsaGdFMVIyaEdDZEcxbmRZc2Nxai1vMTVZcGdxc3ppWU4xcVhn?oc=5" target="_blank">AQS…
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade (NASDAQ:AQST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQcHBGWE5iNmZuRTNXanBFaldVSXhQenJJRkNSWGNZTFg5cVg3RW1JR2F1VXZUZ1djcHp6WE9ySDBLbzJwNG1LbW9qcWdFemhaQUU1TzZ5c1lpQzVFMXlqcTBkZTJjMm9iaVBFcUQyVEVIMTFfcmRaMEFWUHBvX29FVnlhNUU4SnFzXzZsdX…
AQST — Frequently Asked Questions
What is the current share price of Aquestive Therapeutics, Inc. (AQST)?
As of 2026-10-23 16:27 PDT, Aquestive Therapeutics, Inc. (AQST) trades at $4.00 on NasdaqGM. Its 52-week range is $2.95 to $7.49.
What is the market capitalisation of AQST?
Aquestive Therapeutics, Inc. (AQST) has a market capitalisation of $502.05M on NasdaqGM.
What is the P/E ratio of AQST?
AQST trades at a trailing price-to-earnings (P/E) ratio of -6.06. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -10.60.
Is AQST a good stock to buy?
This page provides a data-driven analysis of Aquestive Therapeutics, Inc. (AQST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.